Announced positive results from two pivotal Phase 3 Essential3 studies of ulixacaltamide HCl in essential tremor (ET); Pre-NDA meeting with FDA scheduled for Q4 2025 Plans to accelerate the development of relutrigine in SCN2A and SCN8A DEE patients after comprehensive Type B meeting with FDA Recruitment completed for POWER1 study of vormatrigine in focal onset seizures, with topline results expected in 1H 2026 POWER2 study started, with enrollment expected to complete in 2H 2026 Pro forma cash and investme ...